Neuroleptic malignant syndrome. When levodopa withdrawal is the cause

Area of Science:

• Neurology
• Pharmacology

Background:

• Neuroleptic malignant syndrome (NMS) is a rare but serious adverse drug reaction.
• It is associated with dopamine antagonist medications and, less commonly, with the withdrawal of dopaminergic therapies.

Observation:

• Patients typically present with hyperthermia, altered consciousness, autonomic dysfunction, and muscle rigidity.
• Complications can involve multiple organ systems and pose a significant risk.

Findings:

• The syndrome is linked to the blockade of dopamine receptors or a sudden decrease in dopaminergic stimulation.
• Key clinical features include fever, extreme muscle stiffness (rigidity), and changes in mental status.

Implications:

• Early diagnosis and intervention are critical for improving patient outcomes.
• Management involves discontinuing the offending agent and providing supportive care; reinstating dopaminergic therapy may be necessary if withdrawal is the cause.